JP2019521192A - 心不全の処置方法 - Google Patents

心不全の処置方法 Download PDF

Info

Publication number
JP2019521192A
JP2019521192A JP2019520937A JP2019520937A JP2019521192A JP 2019521192 A JP2019521192 A JP 2019521192A JP 2019520937 A JP2019520937 A JP 2019520937A JP 2019520937 A JP2019520937 A JP 2019520937A JP 2019521192 A JP2019521192 A JP 2019521192A
Authority
JP
Japan
Prior art keywords
alkyl
oxo
dihydrothieno
carboxylic acid
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019520937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521192A5 (enExample
Inventor
マイケル・イー・メンデルソーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardurion Pharmaceuticals Inc
Original Assignee
Cardurion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Inc filed Critical Cardurion Pharmaceuticals Inc
Publication of JP2019521192A publication Critical patent/JP2019521192A/ja
Publication of JP2019521192A5 publication Critical patent/JP2019521192A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019520937A 2016-07-07 2017-07-07 心不全の処置方法 Pending JP2019521192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359695P 2016-07-07 2016-07-07
US62/359,695 2016-07-07
PCT/US2017/041249 WO2018009899A1 (en) 2016-07-07 2017-07-07 Methods for treatment of heart failure

Publications (2)

Publication Number Publication Date
JP2019521192A true JP2019521192A (ja) 2019-07-25
JP2019521192A5 JP2019521192A5 (enExample) 2020-08-13

Family

ID=60912319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520937A Pending JP2019521192A (ja) 2016-07-07 2017-07-07 心不全の処置方法

Country Status (7)

Country Link
US (2) US10870656B2 (enExample)
EP (1) EP3481399A4 (enExample)
JP (1) JP2019521192A (enExample)
KR (1) KR20190049691A (enExample)
AU (1) AU2017292918B2 (enExample)
CA (1) CA3030021A1 (enExample)
WO (1) WO2018009899A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781155A4 (en) * 2018-04-17 2021-10-06 Cardurion Pharmaceuticals, LLC THIENOPYRIMIDINE MEGLUMINE SALTS
CA3132895C (en) 2019-03-08 2024-05-14 Transthera Sciences (Nanjing), Inc. Uses of phosphodiesterase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006135080A1 (ja) * 2005-06-14 2006-12-21 Aska Pharmaceutical Co., Ltd. チエノピリミジン誘導体
US8299083B2 (en) * 2004-08-17 2012-10-30 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
WO2015052065A1 (de) * 2013-10-07 2015-04-16 Bayer Pharma Aktiengesellschaft Cyclische thienouracil-carboxamide und ihre verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
PT2041139E (pt) * 2006-04-26 2012-01-13 Hoffmann La Roche Compostos farmacêuticos
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
KR101721288B1 (ko) * 2010-05-31 2017-03-29 아스카 세이야쿠 가부시키가이샤 티에노피리미딘 유도체의 결정

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299083B2 (en) * 2004-08-17 2012-10-30 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
WO2006135080A1 (ja) * 2005-06-14 2006-12-21 Aska Pharmaceutical Co., Ltd. チエノピリミジン誘導体
WO2015052065A1 (de) * 2013-10-07 2015-04-16 Bayer Pharma Aktiengesellschaft Cyclische thienouracil-carboxamide und ihre verwendung

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE, D.-I., ET AL., NATURE, vol. 519, no. 7544, JPN6021020931, 2015, pages 472 - 476, ISSN: 0004716175 *
NOMOTO, Y., ET AL., CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 39, no. 2, JPN6021020929, 1991, pages 352 - 357, ISSN: 0004716174 *

Also Published As

Publication number Publication date
US10870656B2 (en) 2020-12-22
US20210261567A1 (en) 2021-08-26
KR20190049691A (ko) 2019-05-09
CA3030021A1 (en) 2018-01-11
EP3481399A4 (en) 2020-04-01
EP3481399A1 (en) 2019-05-15
AU2017292918B2 (en) 2021-11-11
AU2017292918A1 (en) 2019-02-07
US20190211028A1 (en) 2019-07-11
WO2018009899A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
CA2846496C (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20080075666A1 (en) Methods and compositions for treating diastolic dysfunction
JP2012105681A (ja) ブルートンチロシンキナーゼ阻害剤
JP7002444B2 (ja) 医薬
JP2024507414A (ja) ウイルス感染症治療のためのｒｏｃｋ２阻害剤
RU2435587C2 (ru) Средство, потенцирующее радиационную терапию
EP3207036A2 (en) Novel small molecule anticancer agents
CN105418599A (zh) 新盐及医药用途
US20210261567A1 (en) Methods for treatment of heart failure
KR20230024354A (ko) 만성 신장 질환을 치료 또는 예방하는 방법
KR20140022052A (ko) 심근 경색 후 환자에서의 심부전 및 부정맥 치료를 위한 ａ２ｂ 아데노신 수용체 안타고니스트의 용도
US20090048173A1 (en) Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors
CN1655820A (zh) Pde5抑制剂与ace抑制剂的药物组合
CN103370309A (zh) 被取代的n-苯乙基三唑酮乙酰胺及其用途
CN1330309C (zh) 用于预防或治疗由eNOS表达而引起的疾病的药物
CN1324618A (zh) 苯甲酸衍生物的制药应用
WO2024167904A1 (en) Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor
US11884649B2 (en) IRE1α inhibitors and uses thereof
US20140228319A1 (en) Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
JP7430916B2 (ja) 心不全の病態の評価のための方法、バイオマーカー、候補化合物の評価方法、医薬用組成物及び心不全の治療剤
CN108774220B (zh) 用于治疗心肌缺血的化合物及其应用
AU2021333580A1 (en) Combination therapies with olig2 inhibitors
CN105646493A (zh) 一种用于预防和治疗器官损伤的化合物及其制备方法和用途
JPWO2019111829A1 (ja) メベンダゾール及び／もしくはイトラコナゾール又はその塩を含有する、肺高血圧症の予防又は治療剤
WO2021235532A1 (ja) 線溶系亢進薬、及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220301